3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
105
Neoplasm Metastasis
6
Neoplasms
4
Breast Diseases
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Hereditary Sensory and Autonomic Neuropathies
3
Carcinoma, Ovarian Epithelial
3
Breast Neoplasms, Male
3
Triple Negative Breast Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Endometrial Neoplasms
2
Breast Cancer Metastatic
2
Anatomic Stage II Breast Cancer AJCC v8
2
Advanced Breast Cancer
2
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Osteitis Deformans
1
Neoplastic Cells, Circulating
1
Mesothelioma
1
Lymphoma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Leukemia
1
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1
Hematologic Neoplasms
1
Interventions
vistusertib
1
ribociclib
1
Tamoxifen
1
Letrozole
1
Goserelin
1
Fulvestrant
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Metastatic Breast Cancer
×
ribociclib
×
Breast
×
Clear all
NCT02278120
2024-03-12
MONALEESA-7
Novartis
Phase 3
Completed
672 enrolled
16 charts
1 FDA